Articles published by Evotec AG
From Evotec AG
Via AccessWire
Evotec and Bristol Myers Squibb Extend and Expand Strategic Partnership in Protein Degradation
May 10, 2022
From Evotec AG
Via AccessWire
Tickers
EVO
Evotec Receives € 3 m Milestone Payment for Bayer Starting Phase II Clinical Development of DNP Programme
March 21, 2022
From Evotec AG
Via AccessWire
Tickers
EVO
Evotec Presents Strategic Roadmap Towards Precision Medicine and Confirms Goals of Action Plan 2025 at Capital Markets Day
March 02, 2022
From Evotec AG
Via AccessWire
Topics
Artificial Intelligence
Exposures
Artificial Intelligence
Tickers
EVO
Evotec Expands Molecular Patient Database with Unique Nephrotic Syndrome Cohort from the University of Bristol
March 01, 2022
From Evotec AG
Via AccessWire
Tickers
EVO
Bayer Discontinues Clinical Development Candidate Eliapixant (BAY1817080), Evotec Regains the Rights to all P2X3 Assets
February 04, 2022
From Evotec AG
Via AccessWire
Tickers
EVO
Evotec Enters iPSC-based Drug Discovery Partnership with Boehringer Ingelheim in Ophthalmology
January 25, 2022
From Evotec AG
Via AccessWire
Tickers
EVO
Evotec SE Reports Results for the First Nine Months 2021 and Provides Corporate Update
November 11, 2021
From Evotec AG
Via AccessWire
Topics
Initial Public Offering
Evotec Reaches Programme Designations in Neuroscience Collaboration with Bristol Myers Squibb
November 10, 2021
From Evotec AG
Via AccessWire
Exposures
Product Safety
Tickers
EVO
Evotec SE Announces Closing of Public Offering
November 09, 2021
From Evotec AG
Via AccessWire
Tickers
EVO
Evotec SE Announces Placement of Its Public Offering of American Depositary Shares
November 03, 2021
From Evotec AG
Via AccessWire
Topics
Regulatory Compliance
Evotec Provides Preliminary Nine Month Financial Results
October 26, 2021
From Evotec AG
Via AccessWire
Evotec SE files Registration Statement for Proposed Offering of American Depositary Shares
October 11, 2021
From Evotec AG
Via AccessWire
Topics
Regulatory Compliance
Evotec Announces Bristol Myers Squibb Opt-in of EVT8683 as the First Programme from iPSC-based Neurodegeneration Collaboration
September 02, 2021
From Evotec AG
Via AccessWire
Exposures
Product Safety
Just - Evotec Biologics Opens J.POD 1 US in Redmond, Washington
August 11, 2021
From Evotec AG
Via AccessWire
Exposures
COVID-19
From Evotec AG
Via AccessWire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.